NSCLC: Influence of Nivolumab plus Ipilimumab on Long-Term Overall survival

被引：0
|
作者：
Manych, Matthias
机构：
来源：
PNEUMOLOGIE | 2020年 / 74卷 / 03期
关键词：
D O I：
10.1055/a-1078-5162
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [1] Long-term Perspective with Nivolumab plus Ipilimumab
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (09)
  • [2] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, C. Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Ferrucci, Pier Francesco
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew
    Marquez-Rodas, Ivan
    Haanen, John B. A. G.
    Guidoboni, Massimo
    Maio, Michele
    Schoffski, Patrick
    Carlino, Matteo S.
    Lebbe, Celeste
    McArthur, Grant
    Ascierto, Paolo A.
    Daniels, Gregory A.
    Long, Georgina, V
    Bas, Tuba
    Ritchings, Corey
    Larkin, James
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
  • [3] First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
    Gettinger, Scott
    Rizvi, Naiyer
    Chow, Laura
    Borghaei, Hossein
    Brahmer, Julie
    Shepherd, Frances
    Ready, Neal
    Gerber, David
    Antonia, Scott
    Goldman, Jonathan W.
    Juergens, Rosalyn
    Geese, William
    Young, Tina
    L, Xuemei, I
    Hellmann, Matthew
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S250 - S251
  • [4] Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
    Hodi, F. Stephen
    Chiarion-Sileni, Vanna
    Lewis, Karl D.
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, Charles Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Queirolo, Paola
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew Graham
    Marquez-Rodas, Ivan
    Haanen, John B. A. G.
    Durani, Piyush
    Wang, Peter
    Wolchok, Jedd D.
    Larkin, James
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
    Motzer, Robert J.
    McDermott, David F.
    Escudier, Bernard
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Barthelemy, Philippe
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Gurney, Howard
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Barrios, Carlos
    Tomita, Yoshihiko
    Castellano, Daniel
    Gruenwald, Viktor
    Rini, Brian, I
    McHenry, M. Brent
    Lee, Chung-Wei
    McCarthy, Jennifer
    Ejzykowicz, Flavia
    Tannir, Nizar M.
    CANCER, 2022, 128 (11) : 2085 - 2097
  • [6] Long-term results with nivolumab and ipilimumab in melanomaCancer therapy
    Vincenzo Giacco
    Nature Cancer, 2025, 6 (3) : 407 - 407
  • [7] NIVOLUMAB PLUS IPILIMUMAB IS WELL TOLERATED AND ACTIVE IN NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (02) : 124 - 124
  • [8] Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab plus Ipilimumab in mNSCLC in CheckMate 227
    Reck, M.
    Worthy, G.
    Yuan, Y.
    Penrod, J. R.
    Lawrance, R.
    Taylor, F.
    Blum, S. I.
    Moisei, A.
    Lee, A.
    Ciuleanu, T. -E.
    Pluzanski, A.
    Lee, J. -S.
    Ramalingam, S.
    Borghaei, H.
    O'Byrne, K.
    Paz-Ares, L.
    Li, L.
    Gupta, R. G.
    Bushong, J.
    Brahmer, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S320 - S321
  • [9] Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817
    Barlesi, F.
    Audigier-Valette, C.
    Felip, E.
    Ciuleanu, T-E.
    Jao, K.
    Rijavec, E.
    Urban, L.
    Aucoin, J-S.
    Zannori, C.
    Vermaelen, K.
    Aren Frontera, O.
    Ready, N.
    Curioni, A.
    Linardou, H.
    Poddubskaya, E.
    Fischer, J. R.
    Pillai, R.
    Li, S.
    Acevedo, A.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 33 - +
  • [10] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. -J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Hogg, D.
    Haanen, J.
    Carlino, M. S.
    Bechter, O.
    Maio, M.
    Marquez-Rodas, I.
    Guidoboni, M.
    McArthur, G.
    Lebbe, C.
    Ascierto, P. A.
    Long, G. V.
    Cebon, J.
    Sosman, J.
    Postow, M. A.
    Callahan, M. K.
    Walker, D.
    Rollin, L.
    Bhore, R.
    Hodi, F. S.
    Larkin, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14): : 1345 - 1356
12345